References
- Bonotis K, Pantelis K, Karaoulanis S, et al. Investigation of factors associated with health-related quality of life and psychological distress in vitiligo. J Dtsch Dermatol Ges 2016; 14: 45-9.
- Bhise SB, Nalawade AD, Wadhawa H. Role of protein tyrosine kinase inhibitors in cancer therapeutics. Indian J Biochem Biophys 2004; 41: 273-80.
- Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000; 19: 5662-79. https://doi.org/10.1038/sj.onc.1203925
- Basak PY, Adiloglu AK, Koc IG, Tas T, Akkaya VB. Evaluation of activatory and inhibitory natural killer cell receptors in non-segmental vitiligo: a flow cytometric study. J Eur Acad Dermatol Venereol 2008; 22: 970-6. https://doi.org/10.1111/j.1468-3083.2008.02681.x
- van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129: 2220-32. https://doi.org/10.1038/jid.2009.32
- Attwa E, Gamil H, Assaf M, Ghonemy S. Over-expression of tumor necrosis factor-alpha in vitiligo lesions after narrow-band UVB therapy: an immunohistochemical study. Arch Dermatol Res 2012; 304: 823-30. https://doi.org/10.1007/s00403-012-1269-6
- Klarquist J, Denman CJ, Hernandez C, et al. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 2010; 23: 276-86. https://doi.org/10.1111/j.1755-148X.2010.00688.x
- Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol 2015; 151: 1110-2. https://doi.org/10.1001/jamadermatol.2015.1520
- Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol Venereol Leprol 2006; 72: 315-21. https://doi.org/10.4103/0378-6323.26722
- Nada HR, El Sharkawy DA, Elmasry MF, Rashed LA, Mamdouh S. Expression of Janus kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study. Arch Dermatol Res 2018; 310: 39-46. https://doi.org/10.1007/s00403-017-1792-6
- Landry DA, Sormany F, Hache J, Roumaud P, Martin LJ. Steroidogenic genes expressions are repressed by high levels of leptin and the JAK/STAT signaling pathway in MA-10 Leydig cells. Mol Cell Biochem 2017; 433: 79-95. https://doi.org/10.1007/s11010-017-3017-x
- Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol 2011; 36: 292-7. https://doi.org/10.1111/j.1365-2230.2010.03972.x
- Qian Y, Liu C, Hartupee J, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007; 8: 247-56. https://doi.org/10.1038/ni1439
- Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 2006; 126: 1102-10. https://doi.org/10.1038/sj.jid.5700125
- Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005; 24: 315-27. https://doi.org/10.1007/s10555-005-1580-1
- Nakagawa R, Yoshida H, Asakawa M, et al. Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC/Nga mice via suppression of Th2 and enhancement of Th17. J Immunol 2011; 187: 4611-20. https://doi.org/10.4049/jimmunol.1100649
Cited by
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases vol.10, pp.None, 2018, https://doi.org/10.3389/fimmu.2019.02342
- Drug Repurposing Patent Applications January-March 2019 vol.17, pp.5, 2019, https://doi.org/10.1089/adt.2019.938
- Vitiligo: A Review vol.236, pp.6, 2020, https://doi.org/10.1159/000506103
- Vitiligo: A focus on pathogenesis and its therapeutic implications vol.48, pp.3, 2018, https://doi.org/10.1111/1346-8138.15743
- Cutaneous JAK Expression in Vitiligo vol.25, pp.2, 2018, https://doi.org/10.1177/1203475420972340
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream vol.13, pp.7, 2018, https://doi.org/10.3390/pharmaceutics13071044
- Acid-responsive PEGylated branching PLGA nanoparticles integrated into dissolving microneedles enhance local treatment of arthritis vol.431, pp.p2, 2018, https://doi.org/10.1016/j.cej.2021.134196